HUP0200223A3 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them - Google Patents

Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them

Info

Publication number
HUP0200223A3
HUP0200223A3 HU0200223A HUP0200223A HUP0200223A3 HU P0200223 A3 HUP0200223 A3 HU P0200223A3 HU 0200223 A HU0200223 A HU 0200223A HU P0200223 A HUP0200223 A HU P0200223A HU P0200223 A3 HUP0200223 A3 HU P0200223A3
Authority
HU
Hungary
Prior art keywords
inhibitors
tace
mmp
tnf
preparation
Prior art date
Application number
HU0200223A
Other languages
Hungarian (hu)
Original Assignee
Wyeth Holdings Corp Madison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corp Madison filed Critical Wyeth Holdings Corp Madison
Publication of HUP0200223A2 publication Critical patent/HUP0200223A2/en
Publication of HUP0200223A3 publication Critical patent/HUP0200223A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0200223A 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them HUP0200223A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23803899A 1999-01-27 1999-01-27

Publications (2)

Publication Number Publication Date
HUP0200223A2 HUP0200223A2 (en) 2002-06-29
HUP0200223A3 true HUP0200223A3 (en) 2002-12-28

Family

ID=22896246

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200223A HUP0200223A3 (en) 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them

Country Status (13)

Country Link
JP (1) JP2002535390A (en)
KR (1) KR20010101732A (en)
AR (1) AR035312A1 (en)
AT (1) ATE309986T1 (en)
AU (1) AU769418B2 (en)
CA (1) CA2356313A1 (en)
CZ (1) CZ20012711A3 (en)
DE (1) DE60024056D1 (en)
EA (1) EA200100806A1 (en)
HU (1) HUP0200223A3 (en)
IL (1) IL144345A0 (en)
NZ (1) NZ512566A (en)
ZA (1) ZA200105222B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003252361A1 (en) * 2002-12-26 2004-07-29 Carna Biosciences Inc. Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
KR20090042779A (en) * 2006-06-30 2009-04-30 쉐링 코포레이션 Substituted piperidines that increase p53 activity and the uses thereof
KR20110022635A (en) * 2008-06-02 2011-03-07 시플라 리미티드 Processes for the synthesis of levocetirizine and intermediates for use therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK115799A3 (en) * 1997-02-27 2000-09-12 American Cyanamid Co N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL ORì (54) SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES
PL342548A1 (en) * 1998-02-19 2001-06-18 American Cyanamid Co N-hydroxy-2-(alkyl-, aryl- or heteroarylsulphanyl-, sulphinyl- or sulphonyl)-3-substituted alkyl-, aryl- or heteroarylamides as inhibitors of matrix metaloproteinases

Also Published As

Publication number Publication date
ZA200105222B (en) 2002-09-25
IL144345A0 (en) 2002-05-23
KR20010101732A (en) 2001-11-14
EA200100806A1 (en) 2002-08-29
JP2002535390A (en) 2002-10-22
AU769418B2 (en) 2004-01-29
DE60024056D1 (en) 2005-12-22
NZ512566A (en) 2004-02-27
HUP0200223A2 (en) 2002-06-29
AR035312A1 (en) 2004-05-12
AU2630500A (en) 2000-08-18
CZ20012711A3 (en) 2002-05-15
ATE309986T1 (en) 2005-12-15
CA2356313A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
HUP0000641A3 (en) Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
HUP0402263A3 (en) Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2002357312A1 (en) Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
HUP0201680A2 (en) Aromatic sulfone hydroxamic acid derivatives metalloprotease inhibitors and pharmaceutical compositions containing them
AU2003282920A8 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
IL136300A0 (en) Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
HUP0103344A3 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them
HUP0201214A3 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
HUP0300195A3 (en) Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them
HUP0200347A2 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0103452A3 (en) Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds
AU2002341715A1 (en) Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
AU2003220401A8 (en) Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
HK1045501A1 (en) Hydroxamic acid derivatives as matrix metalloprotease inhibitors
AU6764400A (en) Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
HUP0200213A3 (en) Alkynyl containing hydroxamic acid compounds as tace inhibitors, process for their preparation and pharmaceutical compositions containing them
NO20013678D0 (en) Alkynyl-Containing Hydroxamic Acid Derivatives, Their Preparation, and Their Use of Summer Matrix Metalloproteinase (MMP) Inhibitors / TNF <alpha>
AU2002346729A1 (en) Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
HUP0200223A2 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them
AU2201701A (en) Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
HUP0003880A3 (en) Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same
HUP0203118A3 (en) Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use
HUP0200729A3 (en) Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them
HUP0203270A3 (en) Hydroxamic acid derivative as inhibitor of the formation of human cd23, process for its preparation and pharmaceutical compositions containing the same
HUP0200605A3 (en) Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees